Clinical Trial Update: Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Razuprotafib in hospitalized COVID-19 patients was terminated; results posted without move to later-phase approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Razuprotafib (razuprotafib)

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: COVID-19, Acute Respiratory Distress Syndrome (ARDS) | Phase 2 | Status: TERMINATED | Results posted: 2023-06-08